

Contents

- 1 History of haemophilia
L. M. Aledort

Review Article

- 3 Diagnosis and treatment of von Willebrand disease: new perspectives and nuances
C. M. Kessler

Original Articles

- 15 Highly purified VWF/FVIII concentrates in the treatment and prophylaxis of von Willebrand disease: the PRO.WILL Study
A. B. Federici
- 25 Fanhdi[®], efficacy and safety in von Willebrand's disease: prospective international study results
I. F. Bello, V. J. Yuste, M. Q. Molina and F. H. Navarro
- 33 Creutzfeldt-Jakob disease: reflections on the risk from blood product therapy
P. Brown
- 41 Safety procedures of coagulation factors
J. I. Jorquera
- 47 Inhibitor development in haemophilia A: the role of von Willebrand factor/factor VIII concentrates
J. Goudemand
- 52 Inhibitors in haemophilia A: current management and open issues
S. Haya, A. Moret, A. R. Cid, V. Cortina, P. Casaña, N. Cabrera and J. A. Aznar
- 61 Factor VIII inhibitors: role of von Willebrand factor on the uptake of factor VIII by dendritic cells
S. V. Kaveri, S. Dasgupta, S. Andre, A.-M. Navarrete, Y. Repessé, B. Wootla and S. Lacroix-Desmazes
- 65 Factor VIII products and inhibitor development: the SIPPET study (survey of inhibitors in plasma-product exposed toddlers)
P. M. Mannucci, A. Gringeri, F. Peyvandi and E. Santagostino
- 69 VWF/FVIII complex and the management of patient with inhibitors: from laboratory to clinical practice
E. Berntorp
- 73 VWF/FVIII concentrates in high-risk immunotolerance: the RESIST study
A. Gringeri